drugset

drugset / Trial / NCT00618735

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

NCT00618735 ↗

Phase 1 Completed 68 enrolled Biogen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.

Timeline

Start: 2008-02
Primary completion: 2010-07
Completion: 2010-12

Publications

Background Saif MW, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, O'Brien S, Stogard C, Von Hoff D. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res. 2014 Jan 15;20(2):445-55. doi: 10.1158/1078-0432.CCR-13-1257. Epub 2013 Oct 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIIB021	Small molecule	—	Oral

Indications